ITGR

Business Context and Reporting Period

This Form 10-Q covers the quarterly and six-month periods ended June 29, 2001, for Wilson Greatbatch Technologies, Inc. (Note: The request metadata listed "Integer Holdings Corp," but the filing text identifies the registrant as Wilson Greatbatch Technologies, Inc.). The Company is a leading developer and manufacturer of power sources, feedthroughs, and wet tantalum capacitors for implantable medical devices, as well as commercial power sources for aerospace and oil/gas exploration.

During the period, the Company completed the acquisition of the Sierra-KD Components division of Maxwell Technologies, Inc. ("Greatbatch-Sierra") on June 18, 2001, for approximately $49.0 million in cash and assumed liabilities.

Key Financial Metrics

Note: Debt figures reflect the restructuring and new facility; prior period debt was significantly lower due to different capital structure.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 34% year-over-year to $62.6 million, driven by the inclusion of Battery Engineering, Inc. (acquired in 2000) and the recent Greatbatch-Sierra acquisition. The Medical segment grew 16% to $48.5 million, while the Commercial segment surged 190% to $14.0 million.
• Profitability Turnaround: The Company reported a net income of $2.6 million compared to a net loss of $0.8 million in the prior year. This was primarily due to a significant reduction in interest expense (down 82% to $1.4 million) following debt restructuring.
• Debt Restructuring: In January 2001, the Company restructured its debt, resulting in an extraordinary loss of $3.0 million (net of tax) due to the write-off of deferred financing fees and a call premium on subordinated notes. In June 2001, the credit facility was amended to $100 million to fund the Greatbatch-Sierra acquisition.
• Working Capital: Accounts receivable and inventories increased significantly ($4.2M and $4.3M respectively) to support higher sales volumes and manufacturing activity.

Guidance, Outlook, and Risks

• Capital Expenditures: Management expects capital expenditures for 2001 to be approximately $8.2 million, with $2.9 million allocated to new product development.
• Liquidity: The Company believes cash generated from operations will be sufficient for working capital and planned capital expenditures. However, they noted that additional financing may be required for future opportunities, with no assurance of availability or terms.
• Recent Equity Offering: On July 31, 2001 (post-period), the Company closed a public offering of 6.75 million shares at $23.00 per share, with net proceeds of approximately $43.6 million intended for general corporate purposes, including debt repayment.
• Accounting Changes: The Company is evaluating the impact of SFAS No. 142, which will cease goodwill amortization effective December 31, 2001, shifting to an impairment-only approach.
• Risks: Key risks include dependence on a limited number of customers, product obsolescence, pricing pressure, reliance on third-party suppliers, and regulatory changes in the healthcare industry.

Investor Verification Checklist

• Acquisition Integration: Verify the integration progress and revenue contribution of the Greatbatch-Sierra division, as purchase price allocation is still subject to revision.
• Debt Covenants: Confirm compliance with the new credit facility's financial covenants related to EBITDA, leverage, and interest coverage ratios.
• Customer Concentration: Assess the risk associated with the termination of royalty revenues from a specific customer mentioned in the text.
• Inventory Levels: Review the significant increase in inventory ($9.5M increase) to ensure it aligns with demand forecasts and does not indicate obsolescence.
• Interest Rate Sensitivity: Monitor the impact of fluctuating interest rates on the $80 million term loan, which bears interest at Prime or LIBOR plus 2.125%.